Manuel José Torres-Jurado

Dr. Manuel José Torres-Jurado

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2025 in Langenbeck's Archives of Surgery
Verified
Journal Article
Open access
PDF file
MTManuel José Torres-Jurado
Manuel José Torres-Jurado
JLJaime López-Sánchez
Jaime López-Sánchez
AVAndrés E. Valera-Montiel
Andrés E. Valera-Montiel
LVLaura Vicente-González
Laura Vicente-González
JTJacobo Trébol-López
Jacobo Trébol-López
FBFrancisco Blanco-Antona
Francisco Blanco-Antona
Purpose: Until now, there have been almost no published references that focus on the postoperative results of patients with complicated primary small bowel lymphoma (PSBL). Our goal is to analyze the postoperative results of patients who underwent emergency surgery for PSBL. Methods: Retrospective observational study of patients diagnosed with complicated PSBL who underwent emergency surgery between 2016 and 2024. The presented gastrointestinal symptoms or findings in the imaging tests that showed hemorrhage, obstruction, or perforation. The incidence of postoperative complications, as well as total (TS) and disease-free survival (DFS) after surgery, were evaluated. Results: Seventeen patients with the diagnosis of PSBL were analyzed. The most common clinical manifestation was intestinal obstruction (41.2%). The most frequent location was the ileum (47%). 40% of patients were diagnosed with diffuse large B-cell lymphoma (41.2%). In total, 12 patients (70.7%) had Lugano stage I disease. The mean TS of the patients was 39 months (range: 32–46). The TS of the patients with B-cell lymphoma was higher than T-cell lymphoma (B-cell lymphoma 27 months vs. T-cell lymphoma 8 months, P = 0.018). The median DFS was 41 months (range: 33–49). The DFS of patients with B-cell lymphoma was higher than T-cell lymphoma (27 months vs. 6 months. P = 0.019). Conclusions: Emergency surgery due to complications in patients with primary intestinal lymphoma does not have negative predictive value on their survival. The prognosis is worse in patients with T-cell primary intestinal lymphomas with a higher rate of postoperative complications and recurrence.

20 May 2024 in Hernia
Verified
Journal Article
Closed access
PDF file
MTManuel José Torres-Jurado
Manuel José Torres-Jurado
MGMaría Teresa Gómez-Hernández
María Teresa Gómez-Hernández
AVAndrés E. Valera-Montiel
Andrés E. Valera-Montiel
LVLaura Vicente-González
Laura Vicente-González
OAOmar Abdel-Lah-Fernández
Omar Abdel-Lah-Fernández
MJMarcelo Fernando Jiménez-López
Marcelo Fernando Jiménez-López

1 April 2026 in Cancers
Verified
Journal Article
Open access
PDF file
MTManuel José Torres-Jurado
Manuel José Torres-Jurado
OAOmar Abdel-Lah-Fernández
Omar Abdel-Lah-Fernández
MAMaría Alejandra Arévalo-González
María Alejandra Arévalo-González
LVLaura Vicente-Gonzalez
Laura Vicente-Gonzalez
NGNEREA GARCÍA GONZÁLEZ
NEREA GARCÍA GONZÁLEZ
FBFrancisco Blanco-Antona
Francisco Blanco-Antona
Objectives: Gastric cancer is one of the leading causes of cancer-related mortality. Sarcopenia, characterized by reduced skeletal muscle mass, strength, and physical performance, is associated with poorer outcomes in gastrointestinal cancers. This study aimed to evaluate the prevalence of sarcopenia, including the Total Psoas Area Index (TPAI), and its association with tumor stage, postoperative complications, and survival in patients with gastric adenocarcinoma. Methods: A retrospective study was conducted, including 79 patients who underwent surgery for gastric adenocarcinoma. Sarcopenia was assessed using a combination of CT-derived muscle mass (TPAI), muscle strength (dynamometry), and functional status (SARC-F). Patients were divided into sarcopenic (SG) and non-sarcopenic (NSG) groups. Clinical and survival data were compared between groups. Results: Sarcopenia was identified in 36.7% of patients. Early-stage disease (I–II) was less frequent in the SG (20.7%) compared to the NSG (44%), whereas stage IV tumors were more common in the SG (20.7% vs. 6%). Sarcopenic patients had a lower body mass index and underwent fewer laparoscopic procedures (44.8% vs. 68%, p = 0.03). Postoperative complications, such as pneumonia and ileus, were more frequent in the SG. Overall survival was significantly lower in the SG (17 vs. 21 months, respectively, p = 0.042), with a reduction in disease-free survival as well. Postoperative TPAI values remained lower in the SG. Conclusions: Sarcopenia, as defined by combined assessment including TPAI, was associated with advanced tumor stage, increased postoperative risk, and reduced survival in patients with gastric cancer. Preoperative assessment of muscle mass may help identify high-risk patients and optimize clinical management.

1 February 2025 in British Journal of Surgery
Verified
Journal Article
Closed access
MTManuel José Torres-Jurado
Manuel José Torres-Jurado
Juan Ramón Gómez LópezJuan Ramón Gómez López
Juan Ramón Gómez López
JDJeancarlos Trujillo Díaz
Jeancarlos Trujillo Díaz
FSFrancesco Schenone
Francesco Schenone
ABAna Benítez-Riesco
Ana Benítez-Riesco
JOJuan Carlos Martín-Del Olmo
Juan Carlos Martín-Del Olmo

9 December 2025 in Updates in Surgery
Verified
Journal Article
Closed access
PDF file
MTManuel José Torres-Jurado
Manuel José Torres-Jurado
JGJuan Ramón Gómez-López
Juan Ramón Gómez-López
JTJeancarlos Jhosmer Trujillo-Díaz
Jeancarlos Jhosmer Trujillo-Díaz
ABAna Benítez-Riesco
Ana Benítez-Riesco
MCMaría Pilar Concejo-Cutoli
María Pilar Concejo-Cutoli
JOJuan Carlos Martín-Del Olmo
Juan Carlos Martín-Del Olmo

1 January 2022 in Revista Española de Enfermedades Digestivas
Verified
Journal Article
Closed access
MTManuel José Torres-Jurado
Manuel José Torres-Jurado
JSJaime López Sánchez
Jaime López Sánchez
OFOmar Abdel-Lah Fernández
Omar Abdel-Lah Fernández
FMFelipe Carlos Parreño Manchado
Felipe Carlos Parreño Manchado
We present the case of a patient with an unusual finding of gastric anthracosis during oncological surgery for gastric adenocarcinoma.